76 related articles for article (PubMed ID: 15569987)
1. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
Raymond E; Kahatt C; Rigolet MH; Sutherland W; Lokiec F; Alexandre J; Tombal B; Elman M; Lee MS; MacDonald JR; Cullen M; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 Nov; 10(22):7566-74. PubMed ID: 15569987
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Seiden MV; Gordon AN; Bodurka DC; Matulonis UA; Penson RT; Reed E; Alberts DS; Weems G; Cullen M; McGuire WP
Gynecol Oncol; 2006 Apr; 101(1):55-61. PubMed ID: 16260029
[TBL] [Abstract][Full Text] [Related]
4. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Yeo W; Boyer M; Chung HC; Ong SY; Lim R; Zee B; Ma B; Lam KC; Mo FK; Ng EK; Ho R; Clarke S; Roh JK; Beale P; Rha SY; Jeung HC; Soo R; Goh BC; Chan AT;
Cancer Chemother Pharmacol; 2007 Feb; 59(3):295-300. PubMed ID: 16783579
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic trial of irofulven.
Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
Sherman CA; Herndon JE; Watson DM; Green MR;
Lung Cancer; 2004 Sep; 45(3):387-92. PubMed ID: 15301880
[TBL] [Abstract][Full Text] [Related]
12. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
13. Irofulven (MGI Pharma).
Baekelandt M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1517-26. PubMed ID: 12431030
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
15. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
Amato RJ; Perez C; Pagliaro L
Invest New Drugs; 2002 Nov; 20(4):413-7. PubMed ID: 12448659
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Invest New Drugs; 2001; 19(1):13-20. PubMed ID: 11291829
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of imexon in patients with advanced malignancy.
Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
